Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials
- 16 November 2015
- journal article
- research article
- Published by Wiley in Respirology
- Vol. 21 (2) , 378-385
Abstract
Background and objective: Obstructive sleep apnoea (OSA) could be an independent risk factor for non‐alcoholic fatty liver disease (NAFLD) occurrence and progression. The impact of continuous positive airway pressure (CPAP) treatment on non‐invasive markers of NAFLD has not been studied. The aim of this study was to evaluate the effect of 6–12 weeks of effective CPAP on the FibroMax test (comprising components including the SteatoTest, NashTest and FibroTest) through three randomized sham controlled studies.Methods: The FibroMax test was performed in 103 obstructive sleep apnoea patients (apnoea + hypopnoea index > 15/h) enrolled in a randomized study comparing sham versus effective CPAP.Results: At baseline, 40.4% of patients in the sham CPAP group and 45.5% in the CPAP group exhibited liver steatosis. Furthermore, 39.6% of patients in the sham CPAP group and 58.4% in the CPAP group displayed borderline or possible non‐alcoholic steatohepatitis (NASH). Six to twelve weeks of effective CPAP did not demonstrate any impact on reducing steatosis, NASH or liver fibrosis even after adjustment for gender, BMI, baseline apnoea + hypopnoea index and severity of liver injury.Conclusion: A number of non‐invasive markers of liver damage are increased in untreated obstructive sleep apnoea patients, potentially contributing to cardiometabolic risk, but they do not improve after 6–12 weeks of effective CPAP treatment.Clinical trial registration: NCT01196845 (ADISAS), NCT00464659 (MneSAS) and NCT00669695 (StatinflaSAS) at ClinicalTrials.gov.Keywords
This publication has 32 references indexed in Scilit:
- The Interactions of Nonalcoholic Fatty Liver Disease and Cardiovascular DiseasesClinics in Liver Disease, 2014
- Characteristics and diagnosis of NAFLD/NASHJournal of Gastroenterology and Hepatology, 2013
- Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obeseJournal of Hepatology, 2012
- Sleep apnoea syndrome in 2011: current concepts and future directionsEuropean Respiratory Review, 2011
- NASH: A global health problemHepatology Research, 2011
- Human Fatty Liver Disease: Old Questions and New InsightsScience, 2011
- Sleep, sleep-disordered breathing and metabolic consequencesEuropean Respiratory Journal, 2009
- Apnoeic–hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitisLiver International, 2008
- FibroMAX™: towards a new universal biomarker of liver disease?Expert Review of Molecular Diagnostics, 2007
- Pathogenesis of Non-alcoholic Steatohepatitis: Human DataClinics in Liver Disease, 2007